Presentation is loading. Please wait.

Presentation is loading. Please wait.

Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer  Judith Elizabeth Carser, MB, BCh, MRCR, Yvonne Jane Summers,

Published by῾Ερμιόνη Βασιλείου Modified over 5 years ago

Similar presentations

Presentation on theme: "Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer  Judith Elizabeth Carser, MB, BCh, MRCR, Yvonne Jane Summers,"— Presentation transcript:

1 Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer 
Judith Elizabeth Carser, MB, BCh, MRCR, Yvonne Jane Summers, PhD, MBChB, MRCP  Journal of Thoracic Oncology  Volume 1, Issue 9, Pages (November 2006) DOI: /S (15) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Chest computed tomographic scan before treatment.
Journal of Thoracic Oncology 2006 1, DOI: ( /S (15) ) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Chest computed tomographic scan after 3 months' treatment with Erlotinib. Journal of Thoracic Oncology 2006 1, DOI: ( /S (15) ) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Excessive eyelash growth after 8 months of treatment.
Journal of Thoracic Oncology 2006 1, DOI: ( /S (15) ) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer  Judith Elizabeth Carser, MB, BCh, MRCR, Yvonne Jane Summers,"

Similar presentations

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages 1862-1863.

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages
Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.
Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non– Small-Cell Lung Cancer Yen-Ting Lin, MD, Yu-Fen Wang, MD, James Chih-Hsin.

Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non– Small-Cell Lung Cancer Yen-Ting Lin, MD, Yu-Fen Wang, MD, James Chih-Hsin.
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers 

Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers 
Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
Rebecca Muirhead, MBChB, MRCP, Stuart G

Rebecca Muirhead, MBChB, MRCP, Stuart G
Dramatic Response to Low-Dose Erlotinib of Epidermal Growth Factor Receptor Mutation-Positive Recurrent Non-small Cell Lung Cancer After Severe Cutaneous.

Dramatic Response to Low-Dose Erlotinib of Epidermal Growth Factor Receptor Mutation-Positive Recurrent Non-small Cell Lung Cancer After Severe Cutaneous.
OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer

OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer
Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,
The Moth-Eaten Lung Journal of Thoracic Oncology

The Moth-Eaten Lung Journal of Thoracic Oncology
The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 
Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP 

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP 
Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease  Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease  Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.
Surgical Treatment of a Giant Symptomatic Cardiac Lipoma

Surgical Treatment of a Giant Symptomatic Cardiac Lipoma
EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients  Jangchul Park, MD, Chiaki Kondo, MD, Junichi.

EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients  Jangchul Park, MD, Chiaki Kondo, MD, Junichi.

Similar presentations

Ads by Google